Journal of the American Society of Nephrology, Vol 5, 1517-1529, Copyright © 1995 by American Society of Nephrology

REGULAR ARTICLES

Multicenter trial of erythropoietin in patients on peritoneal dialysis

AR Nissenson, S Korbet, M Faber, J Burkart, D Gentile, R Hamburger, W Mattern, M Schreiber, R Swartz and J Van Stone
University of California at Los Angeles.

A randomized, double-blind, placebo-controlled, multicenter trial was performed to assess the safety and efficacy of subcutaneous recombinant erythropoietin (EPO) in peritoneal dialysis patients. Seventy-eight patients were randomized to receive EPO and 74 received placebo during the first 12 wk. After this, placebo patients with hematocrit less than 32% entered the EPO maintenance phase along with the initial EPO patients. Hematocrit rose significantly in the EPO group from 23.8 to 32% after 6 wk, and this was sustained at 33.7% at 12 wk. In the placebo group, the prestudy hematocrit was 23.8% as well, and no significant change in hematocrit occurred over 12 wk. Concomitant with the rise in hematocrit, transfusion requirements fell only in the EPO group. Eighty-eight percent of patients receiving EPO had their anemia ameliorated by Week 12 of the study. There was a wide range of dosage requirements during the maintenance phase, ranging from 8,000 U thrice weekly to 4,000 U every other week. Adverse events after EPO were similar to those seen in hemodialysis patients given this agent, with hypertension developing or worsening in 55% of EPO patients during the initial 12 wk of therapy. Blood pressure was more likely to rise in patients with hypertension before receiving EPO. EPO is safe and effective in peritoneal dialysis patients, as it is in hemodialysis patients. Other than a rise in blood pressure, which is manageable with antihypertensives and ultrafiltration with dialysis, no serious side effects are seen. The optimal target hematocrit, effects of anemia improvement on quality of life, and end-organ (heart, brain) effects of anemia improvement in this patient population require further study.

This article has been cited by other articles:

				J. Siegel, J. Jorgenson, P. E. Johnson, D. F. Brophy, T. Comstock, A. Feng, and P. Audhya Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings Am. J. Health Syst. Pharm., September 15, 2008; 65(18): 1711 - 1719. [Abstract] [Full Text] [PDF]

				R. N. Foley Do We Know the Correct Hemoglobin Target for Anemic Patients with Chronic Kidney Disease? Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 678 - 684. [Abstract] [Full Text] [PDF]

				H. Singh, J. Reed, S. Noble, J. L. Cangiano, D. B. Van Wyck, and for the United States Iron Sucrose (Venofer) Clini Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia: A Randomized, Controlled Trial Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 475 - 482. [Abstract] [Full Text] [PDF]

				D. H. Catlin, A. Breidbach, S. Elliott, and J. Glaspy Comparison of the Isoelectric Focusing Patterns of Darbepoetin Alfa, Recombinant Human Erythropoietin, and Endogenous Erythropoietin from Human Urine Clin. Chem., November 1, 2002; 48(11): 2057 - 2059. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673